Beyond that the reliability of PD-L1 assays to predict ICI response is reduced by various aspects such as non-immunity dependent upregulation of PD-L1 expression (e.g. via PTEN) [32] or intratumoral heterogeneity and dynamic alteration by treatment and cancer progression [24]. Here, PTEN is linked to cancer.